nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Doxorubicin—thyroid cancer	0.249	0.542	CbGbCtD
Bosentan—CYP2C9—Sorafenib—thyroid cancer	0.0724	0.158	CbGbCtD
Bosentan—CYP3A4—Vandetanib—thyroid cancer	0.0698	0.152	CbGbCtD
Bosentan—CYP3A4—Sorafenib—thyroid cancer	0.0421	0.0918	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—thyroid cancer	0.0255	0.0557	CbGbCtD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0146	0.121	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0105	0.0863	CbGpPWpGaD
Bosentan—EDNRB—Endothelin Pathways—CALCA—thyroid cancer	0.00583	0.048	CbGpPWpGaD
Bosentan—EDNRA—Endothelin Pathways—CALCA—thyroid cancer	0.00417	0.0344	CbGpPWpGaD
Bosentan—EDNRB—Peptide GPCRs—TSHR—thyroid cancer	0.00408	0.0336	CbGpPWpGaD
Bosentan—ABCB11—Recycling of bile acids and salts—RXRA—thyroid cancer	0.00403	0.0332	CbGpPWpGaD
Bosentan—ABCB11—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00351	0.029	CbGpPWpGaD
Bosentan—EDNRA—Peptide GPCRs—TSHR—thyroid cancer	0.00292	0.0241	CbGpPWpGaD
Bosentan—ABCB11—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—RXRA—thyroid cancer	0.00291	0.024	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—thyroid cancer	0.0028	0.0231	CbGpPWpGaD
Bosentan—ABCB11—Synthesis of bile acids and bile salts—RXRA—thyroid cancer	0.00265	0.0219	CbGpPWpGaD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00263	0.0216	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CALCB—thyroid cancer	0.00212	0.0175	CbGpPWpGaD
Bosentan—ABCB11—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.00211	0.0174	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00188	0.0155	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CALCB—thyroid cancer	0.00152	0.0125	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0015	0.0123	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—SST—thyroid cancer	0.00149	0.0123	CbGpPWpGaD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00139	0.0115	CbGpPWpGaD
Bosentan—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00129	0.0107	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00129	0.0106	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CALCB—thyroid cancer	0.0012	0.00986	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00118	0.00971	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CALCB—thyroid cancer	0.00109	0.00896	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—SST—thyroid cancer	0.00107	0.0088	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.001	0.00825	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—TSHR—thyroid cancer	0.00098	0.00808	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000921	0.00759	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CALCB—thyroid cancer	0.000856	0.00706	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000843	0.00695	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—PTCH1—thyroid cancer	0.000834	0.00687	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—HRAS—thyroid cancer	0.000825	0.0068	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CALCB—thyroid cancer	0.000778	0.00641	CbGpPWpGaD
Bosentan—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000773	0.00637	CbGpPWpGaD
Bosentan—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000773	0.00637	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—SST—thyroid cancer	0.000762	0.00628	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CALCA—thyroid cancer	0.000734	0.00605	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—AKT1—thyroid cancer	0.000729	0.00601	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000717	0.00591	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—TSHR—thyroid cancer	0.000702	0.00578	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000682	0.00562	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CALCB—thyroid cancer	0.000642	0.00529	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000641	0.00528	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000639	0.00152	CcSEcCtD
Bosentan—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000625	0.00149	CcSEcCtD
Bosentan—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000622	0.00148	CcSEcCtD
Bosentan—Urticaria—Sorafenib—thyroid cancer	0.000621	0.00148	CcSEcCtD
Bosentan—Body temperature increased—Sorafenib—thyroid cancer	0.000618	0.00147	CcSEcCtD
Bosentan—Abdominal pain—Sorafenib—thyroid cancer	0.000618	0.00147	CcSEcCtD
Bosentan—Renal impairment—Epirubicin—thyroid cancer	0.000617	0.00147	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TRIM33—thyroid cancer	0.000609	0.00502	CbGpPWpGaD
Bosentan—Eczema—Doxorubicin—thyroid cancer	0.000605	0.00144	CcSEcCtD
Bosentan—Hepatic failure—Doxorubicin—thyroid cancer	0.000605	0.00144	CcSEcCtD
Bosentan—Cardiac failure—Epirubicin—thyroid cancer	0.000602	0.00143	CcSEcCtD
Bosentan—Hypoglycaemia—Epirubicin—thyroid cancer	0.000602	0.00143	CcSEcCtD
Bosentan—Cerebrovascular accident—Epirubicin—thyroid cancer	0.0006	0.00143	CcSEcCtD
Bosentan—Lethargy—Epirubicin—thyroid cancer	0.0006	0.00143	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—PTCH1—thyroid cancer	0.000597	0.00492	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—HRAS—thyroid cancer	0.000591	0.00487	CbGpPWpGaD
Bosentan—Hyponatraemia—Epirubicin—thyroid cancer	0.00059	0.0014	CcSEcCtD
Bosentan—Pain in extremity—Epirubicin—thyroid cancer	0.000587	0.0014	CcSEcCtD
Bosentan—Affect lability—Epirubicin—thyroid cancer	0.000578	0.00138	CcSEcCtD
Bosentan—Hypersensitivity—Sorafenib—thyroid cancer	0.000576	0.00137	CcSEcCtD
Bosentan—Renal impairment—Doxorubicin—thyroid cancer	0.000571	0.00136	CcSEcCtD
Bosentan—Asthenia—Sorafenib—thyroid cancer	0.000561	0.00133	CcSEcCtD
Bosentan—Cardiac arrest—Epirubicin—thyroid cancer	0.000559	0.00133	CcSEcCtD
Bosentan—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000557	0.00133	CcSEcCtD
Bosentan—Cardiac failure—Doxorubicin—thyroid cancer	0.000557	0.00133	CcSEcCtD
Bosentan—Mood swings—Epirubicin—thyroid cancer	0.000557	0.00132	CcSEcCtD
Bosentan—Lethargy—Doxorubicin—thyroid cancer	0.000555	0.00132	CcSEcCtD
Bosentan—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000555	0.00132	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—TSHR—thyroid cancer	0.000554	0.00457	CbGpPWpGaD
Bosentan—Pruritus—Sorafenib—thyroid cancer	0.000553	0.00132	CcSEcCtD
Bosentan—Dehydration—Epirubicin—thyroid cancer	0.000546	0.0013	CcSEcCtD
Bosentan—Hyponatraemia—Doxorubicin—thyroid cancer	0.000546	0.0013	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—SST—thyroid cancer	0.000546	0.0045	CbGpPWpGaD
Bosentan—Pain in extremity—Doxorubicin—thyroid cancer	0.000544	0.00129	CcSEcCtD
Bosentan—Liver function test abnormal—Epirubicin—thyroid cancer	0.000542	0.00129	CcSEcCtD
Bosentan—Dry skin—Epirubicin—thyroid cancer	0.000538	0.00128	CcSEcCtD
Bosentan—Abdominal pain upper—Epirubicin—thyroid cancer	0.000537	0.00128	CcSEcCtD
Bosentan—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000537	0.00128	CcSEcCtD
Bosentan—Affect lability—Doxorubicin—thyroid cancer	0.000535	0.00127	CcSEcCtD
Bosentan—Hypokalaemia—Epirubicin—thyroid cancer	0.000535	0.00127	CcSEcCtD
Bosentan—Diarrhoea—Sorafenib—thyroid cancer	0.000535	0.00127	CcSEcCtD
Bosentan—Nasopharyngitis—Epirubicin—thyroid cancer	0.000525	0.00125	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—CALCA—thyroid cancer	0.000525	0.00433	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—AKT1—thyroid cancer	0.000522	0.0043	CbGpPWpGaD
Bosentan—Cardiac arrest—Doxorubicin—thyroid cancer	0.000517	0.00123	CcSEcCtD
Bosentan—Dizziness—Sorafenib—thyroid cancer	0.000517	0.00123	CcSEcCtD
Bosentan—Mood swings—Doxorubicin—thyroid cancer	0.000515	0.00123	CcSEcCtD
Bosentan—Abdominal distension—Epirubicin—thyroid cancer	0.000511	0.00122	CcSEcCtD
Bosentan—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00051	0.0042	CbGpPWpGaD
Bosentan—Asthma—Epirubicin—thyroid cancer	0.000508	0.00121	CcSEcCtD
Bosentan—Influenza—Epirubicin—thyroid cancer	0.000508	0.00121	CcSEcCtD
Bosentan—Dehydration—Doxorubicin—thyroid cancer	0.000506	0.0012	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—TSHR—thyroid cancer	0.000503	0.00415	CbGpPWpGaD
Bosentan—Eosinophilia—Epirubicin—thyroid cancer	0.000503	0.0012	CcSEcCtD
Bosentan—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000502	0.00119	CcSEcCtD
Bosentan—Dry skin—Doxorubicin—thyroid cancer	0.000498	0.00119	CcSEcCtD
Bosentan—Vomiting—Sorafenib—thyroid cancer	0.000497	0.00118	CcSEcCtD
Bosentan—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000496	0.00118	CcSEcCtD
Bosentan—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000496	0.00118	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000495	0.00408	CbGpPWpGaD
Bosentan—Hypokalaemia—Doxorubicin—thyroid cancer	0.000495	0.00118	CcSEcCtD
Bosentan—Angina pectoris—Epirubicin—thyroid cancer	0.000495	0.00118	CcSEcCtD
Bosentan—Rash—Sorafenib—thyroid cancer	0.000493	0.00117	CcSEcCtD
Bosentan—Dermatitis—Sorafenib—thyroid cancer	0.000492	0.00117	CcSEcCtD
Bosentan—Headache—Sorafenib—thyroid cancer	0.000489	0.00117	CcSEcCtD
Bosentan—Bronchitis—Epirubicin—thyroid cancer	0.000488	0.00116	CcSEcCtD
Bosentan—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000486	0.00116	CcSEcCtD
Bosentan—Neutropenia—Epirubicin—thyroid cancer	0.000475	0.00113	CcSEcCtD
Bosentan—Dysuria—Epirubicin—thyroid cancer	0.000475	0.00113	CcSEcCtD
Bosentan—Abdominal distension—Doxorubicin—thyroid cancer	0.000473	0.00113	CcSEcCtD
Bosentan—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000472	0.00112	CcSEcCtD
Bosentan—Influenza—Doxorubicin—thyroid cancer	0.00047	0.00112	CcSEcCtD
Bosentan—Asthma—Doxorubicin—thyroid cancer	0.00047	0.00112	CcSEcCtD
Bosentan—Pollakiuria—Epirubicin—thyroid cancer	0.000469	0.00112	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000467	0.00385	CbGpPWpGaD
Bosentan—Eosinophilia—Doxorubicin—thyroid cancer	0.000465	0.00111	CcSEcCtD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000465	0.00383	CbGpPWpGaD
Bosentan—Nausea—Sorafenib—thyroid cancer	0.000464	0.0011	CcSEcCtD
Bosentan—Weight increased—Epirubicin—thyroid cancer	0.000462	0.0011	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CALCB—thyroid cancer	0.000459	0.00379	CbGpPWpGaD
Bosentan—Weight decreased—Epirubicin—thyroid cancer	0.000459	0.00109	CcSEcCtD
Bosentan—Hyperglycaemia—Epirubicin—thyroid cancer	0.000458	0.00109	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—thyroid cancer	0.000458	0.00109	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—thyroid cancer	0.000455	0.00108	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—thyroid cancer	0.000453	0.00108	CcSEcCtD
Bosentan—Infestation—Epirubicin—thyroid cancer	0.000453	0.00108	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—thyroid cancer	0.000452	0.00108	CcSEcCtD
Bosentan—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.00045	0.00371	CbGpPWpGaD
Bosentan—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000449	0.00107	CcSEcCtD
Bosentan—Renal failure—Epirubicin—thyroid cancer	0.000445	0.00106	CcSEcCtD
Bosentan—ABCB11—Metabolism—MINPP1—thyroid cancer	0.000443	0.00365	CbGpPWpGaD
Bosentan—Stomatitis—Epirubicin—thyroid cancer	0.000441	0.00105	CcSEcCtD
Bosentan—Jaundice—Epirubicin—thyroid cancer	0.000441	0.00105	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—thyroid cancer	0.00044	0.00105	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—thyroid cancer	0.00044	0.00105	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—thyroid cancer	0.000439	0.00105	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—thyroid cancer	0.000439	0.00105	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000437	0.00104	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—TRIM33—thyroid cancer	0.000436	0.00359	CbGpPWpGaD
Bosentan—Pollakiuria—Doxorubicin—thyroid cancer	0.000434	0.00103	CcSEcCtD
Bosentan—Haematuria—Epirubicin—thyroid cancer	0.000432	0.00103	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—SST—thyroid cancer	0.000431	0.00355	CbGpPWpGaD
Bosentan—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000428	0.00102	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PTCH1—thyroid cancer	0.000428	0.00353	CbGpPWpGaD
Bosentan—Weight increased—Doxorubicin—thyroid cancer	0.000428	0.00102	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—thyroid cancer	0.000427	0.00102	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—thyroid cancer	0.000425	0.00101	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—thyroid cancer	0.000425	0.00101	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000424	0.00101	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000423	0.00348	CbGpPWpGaD
Bosentan—Pneumonia—Doxorubicin—thyroid cancer	0.000421	0.001	CcSEcCtD
Bosentan—Infestation—Doxorubicin—thyroid cancer	0.000419	0.000997	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—thyroid cancer	0.000419	0.000997	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000415	0.000989	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—CALCA—thyroid cancer	0.000415	0.00342	CbGpPWpGaD
Bosentan—Bradycardia—Epirubicin—thyroid cancer	0.000414	0.000985	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—thyroid cancer	0.000412	0.00098	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—thyroid cancer	0.000408	0.000972	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—thyroid cancer	0.000408	0.000972	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—thyroid cancer	0.000408	0.000972	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—thyroid cancer	0.000407	0.000969	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—thyroid cancer	0.000407	0.000969	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—thyroid cancer	0.000406	0.000968	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—thyroid cancer	0.000406	0.000968	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TCF7L1—thyroid cancer	0.000406	0.00335	CbGpPWpGaD
Bosentan—Hypoaesthesia—Epirubicin—thyroid cancer	0.000404	0.000963	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—thyroid cancer	0.000401	0.000956	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—thyroid cancer	0.0004	0.000953	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—thyroid cancer	0.000399	0.000951	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—thyroid cancer	0.000398	0.000948	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—TSHR—thyroid cancer	0.000397	0.00327	CbGpPWpGaD
Bosentan—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000396	0.000943	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—thyroid cancer	0.000395	0.000941	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—thyroid cancer	0.000393	0.000936	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—SST—thyroid cancer	0.000391	0.00322	CbGpPWpGaD
Bosentan—Erythema multiforme—Epirubicin—thyroid cancer	0.000384	0.000915	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—thyroid cancer	0.000383	0.000911	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—thyroid cancer	0.00038	0.000904	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—thyroid cancer	0.000379	0.000902	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000379	0.00312	CbGpPWpGaD
Bosentan—Haemoglobin—Doxorubicin—thyroid cancer	0.000378	0.0009	CcSEcCtD
Bosentan—Flushing—Epirubicin—thyroid cancer	0.000377	0.000898	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—thyroid cancer	0.000377	0.000898	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CALCA—thyroid cancer	0.000377	0.0031	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NDUFA13—thyroid cancer	0.000377	0.0031	CbGpPWpGaD
Bosentan—Haemorrhage—Doxorubicin—thyroid cancer	0.000376	0.000895	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—thyroid cancer	0.000376	0.000895	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000374	0.000891	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000371	0.000884	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—thyroid cancer	0.00037	0.000882	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—thyroid cancer	0.000369	0.000878	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—thyroid cancer	0.000369	0.000878	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—thyroid cancer	0.000367	0.000874	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—thyroid cancer	0.000366	0.000872	CcSEcCtD
Bosentan—Chills—Epirubicin—thyroid cancer	0.000365	0.000868	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000364	0.003	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—TSHR—thyroid cancer	0.00036	0.00297	CbGpPWpGaD
Bosentan—Mental disorder—Epirubicin—thyroid cancer	0.000356	0.000848	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—thyroid cancer	0.000356	0.000846	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000354	0.00292	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CHST14—thyroid cancer	0.000354	0.00292	CbGpPWpGaD
Bosentan—Malnutrition—Epirubicin—thyroid cancer	0.000354	0.000842	CcSEcCtD
Bosentan—Erythema—Epirubicin—thyroid cancer	0.000354	0.000842	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—thyroid cancer	0.000351	0.000837	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—thyroid cancer	0.000351	0.000835	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—thyroid cancer	0.000349	0.000831	CcSEcCtD
Bosentan—Flushing—Doxorubicin—thyroid cancer	0.000349	0.000831	CcSEcCtD
Bosentan—Flatulence—Epirubicin—thyroid cancer	0.000349	0.00083	CcSEcCtD
Bosentan—Back pain—Epirubicin—thyroid cancer	0.000342	0.000815	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—thyroid cancer	0.000341	0.000812	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CDK1—thyroid cancer	0.000341	0.00281	CbGpPWpGaD
Bosentan—Muscle spasms—Epirubicin—thyroid cancer	0.00034	0.00081	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—thyroid cancer	0.00034	0.000809	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000339	0.000807	CcSEcCtD
Bosentan—Chills—Doxorubicin—thyroid cancer	0.000337	0.000803	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—thyroid cancer	0.000333	0.000794	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—thyroid cancer	0.000329	0.000784	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—thyroid cancer	0.000327	0.000779	CcSEcCtD
Bosentan—Erythema—Doxorubicin—thyroid cancer	0.000327	0.000779	CcSEcCtD
Bosentan—Anaemia—Epirubicin—thyroid cancer	0.000327	0.000779	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—thyroid cancer	0.000323	0.000768	CcSEcCtD
Bosentan—Vertigo—Epirubicin—thyroid cancer	0.000318	0.000757	CcSEcCtD
Bosentan—Syncope—Epirubicin—thyroid cancer	0.000317	0.000755	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—thyroid cancer	0.000317	0.000754	CcSEcCtD
Bosentan—Back pain—Doxorubicin—thyroid cancer	0.000317	0.000754	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—thyroid cancer	0.000315	0.000749	CcSEcCtD
Bosentan—Palpitations—Epirubicin—thyroid cancer	0.000313	0.000744	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—thyroid cancer	0.000311	0.00074	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000309	0.00255	CbGpPWpGaD
Bosentan—Cough—Epirubicin—thyroid cancer	0.000309	0.000735	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—thyroid cancer	0.000309	0.000734	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—SST—thyroid cancer	0.000308	0.00254	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000308	0.00254	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000307	0.00253	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PTCH1—thyroid cancer	0.000306	0.00252	CbGpPWpGaD
Bosentan—Anaemia—Doxorubicin—thyroid cancer	0.000303	0.00072	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000302	0.00249	CbGpPWpGaD
Bosentan—Arthralgia—Epirubicin—thyroid cancer	0.000301	0.000717	CcSEcCtD
Bosentan—Chest pain—Epirubicin—thyroid cancer	0.000301	0.000717	CcSEcCtD
Bosentan—Anxiety—Epirubicin—thyroid cancer	0.0003	0.000715	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000299	0.000712	CcSEcCtD
Bosentan—Discomfort—Epirubicin—thyroid cancer	0.000298	0.000708	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TSHR—thyroid cancer	0.000297	0.00245	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CALCA—thyroid cancer	0.000297	0.00245	CbGpPWpGaD
Bosentan—Dry mouth—Epirubicin—thyroid cancer	0.000295	0.000701	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—thyroid cancer	0.000294	0.0007	CcSEcCtD
Bosentan—Syncope—Doxorubicin—thyroid cancer	0.000294	0.000699	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—thyroid cancer	0.000293	0.000698	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PRKAR1A—thyroid cancer	0.000292	0.00241	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TCF7L1—thyroid cancer	0.000291	0.0024	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—thyroid cancer	0.000289	0.000689	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—thyroid cancer	0.000289	0.000687	CcSEcCtD
Bosentan—Oedema—Epirubicin—thyroid cancer	0.000289	0.000687	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—thyroid cancer	0.000288	0.000685	CcSEcCtD
Bosentan—Infection—Epirubicin—thyroid cancer	0.000287	0.000683	CcSEcCtD
Bosentan—Cough—Doxorubicin—thyroid cancer	0.000286	0.00068	CcSEcCtD
Bosentan—ABCB11—Metabolism—HPGD—thyroid cancer	0.000285	0.00235	CbGpPWpGaD
Bosentan—Shock—Epirubicin—thyroid cancer	0.000284	0.000676	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—thyroid cancer	0.000283	0.000674	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—thyroid cancer	0.000283	0.000673	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—thyroid cancer	0.000282	0.000671	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—thyroid cancer	0.00028	0.000668	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—SST—thyroid cancer	0.00028	0.00231	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MEN1—thyroid cancer	0.000279	0.0023	CbGpPWpGaD
Bosentan—Hyperhidrosis—Epirubicin—thyroid cancer	0.000279	0.000665	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—thyroid cancer	0.000279	0.000664	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—thyroid cancer	0.000279	0.000664	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—thyroid cancer	0.000278	0.000661	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000277	0.000659	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—thyroid cancer	0.000275	0.000656	CcSEcCtD
Bosentan—Anorexia—Epirubicin—thyroid cancer	0.000275	0.000655	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—thyroid cancer	0.000273	0.000649	CcSEcCtD
Bosentan—Hypotension—Epirubicin—thyroid cancer	0.00027	0.000642	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CALCA—thyroid cancer	0.00027	0.00222	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000269	0.00221	CbGpPWpGaD
Bosentan—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000267	0.000636	CcSEcCtD
Bosentan—Oedema—Doxorubicin—thyroid cancer	0.000267	0.000636	CcSEcCtD
Bosentan—Infection—Doxorubicin—thyroid cancer	0.000265	0.000632	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000263	0.000626	CcSEcCtD
Bosentan—Shock—Doxorubicin—thyroid cancer	0.000263	0.000626	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—thyroid cancer	0.000262	0.000624	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000262	0.000623	CcSEcCtD
Bosentan—Insomnia—Epirubicin—thyroid cancer	0.000261	0.000622	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—thyroid cancer	0.000261	0.000621	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00026	0.00215	CbGpPWpGaD
Bosentan—Skin disorder—Doxorubicin—thyroid cancer	0.00026	0.000618	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—thyroid cancer	0.000259	0.000617	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000258	0.000615	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—thyroid cancer	0.000257	0.000613	CcSEcCtD
Bosentan—Somnolence—Epirubicin—thyroid cancer	0.000257	0.000611	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—thyroid cancer	0.000255	0.000606	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—thyroid cancer	0.000254	0.000605	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PTCH1—thyroid cancer	0.000253	0.00208	CbGpPWpGaD
Bosentan—Decreased appetite—Epirubicin—thyroid cancer	0.000251	0.000598	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00025	0.00206	CbGpPWpGaD
Bosentan—Hypotension—Doxorubicin—thyroid cancer	0.00025	0.000594	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000249	0.000593	CcSEcCtD
Bosentan—Fatigue—Epirubicin—thyroid cancer	0.000249	0.000593	CcSEcCtD
Bosentan—Constipation—Epirubicin—thyroid cancer	0.000247	0.000588	CcSEcCtD
Bosentan—Pain—Epirubicin—thyroid cancer	0.000247	0.000588	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CDK1—thyroid cancer	0.000244	0.00201	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000243	0.000579	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—thyroid cancer	0.000242	0.000575	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—thyroid cancer	0.00024	0.000571	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—thyroid cancer	0.000238	0.000567	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—thyroid cancer	0.000238	0.000565	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000236	0.000562	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—thyroid cancer	0.000235	0.00056	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—thyroid cancer	0.000232	0.000553	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000232	0.00191	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SST—thyroid cancer	0.000231	0.0019	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000231	0.000549	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—thyroid cancer	0.00023	0.000548	CcSEcCtD
Bosentan—Urticaria—Epirubicin—thyroid cancer	0.000229	0.000546	CcSEcCtD
Bosentan—Constipation—Doxorubicin—thyroid cancer	0.000228	0.000544	CcSEcCtD
Bosentan—Pain—Doxorubicin—thyroid cancer	0.000228	0.000544	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—thyroid cancer	0.000228	0.000543	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—thyroid cancer	0.000228	0.000543	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CALCA—thyroid cancer	0.000222	0.00183	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000221	0.00182	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000218	0.00052	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000214	0.00176	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—thyroid cancer	0.000213	0.000506	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—TSHR—thyroid cancer	0.000213	0.00175	CbGpPWpGaD
Bosentan—Urticaria—Doxorubicin—thyroid cancer	0.000212	0.000505	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—thyroid cancer	0.000211	0.000503	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—thyroid cancer	0.000211	0.000503	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PRKAR1A—thyroid cancer	0.000209	0.00172	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—thyroid cancer	0.000207	0.000493	CcSEcCtD
Bosentan—Pruritus—Epirubicin—thyroid cancer	0.000204	0.000486	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CDK1—thyroid cancer	0.000201	0.00166	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000201	0.00166	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MEN1—thyroid cancer	0.0002	0.00165	CbGpPWpGaD
Bosentan—Diarrhoea—Epirubicin—thyroid cancer	0.000198	0.00047	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—thyroid cancer	0.000197	0.000469	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—thyroid cancer	0.000192	0.000456	CcSEcCtD
Bosentan—Dizziness—Epirubicin—thyroid cancer	0.000191	0.000455	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—thyroid cancer	0.000189	0.00045	CcSEcCtD
Bosentan—Vomiting—Epirubicin—thyroid cancer	0.000184	0.000437	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—thyroid cancer	0.000183	0.000435	CcSEcCtD
Bosentan—Rash—Epirubicin—thyroid cancer	0.000182	0.000433	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—thyroid cancer	0.000182	0.000433	CcSEcCtD
Bosentan—Headache—Epirubicin—thyroid cancer	0.000181	0.000431	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PTCH1—thyroid cancer	0.000181	0.00149	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—thyroid cancer	0.000177	0.000421	CcSEcCtD
Bosentan—Nausea—Epirubicin—thyroid cancer	0.000172	0.000408	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—thyroid cancer	0.00017	0.000404	CcSEcCtD
Bosentan—Rash—Doxorubicin—thyroid cancer	0.000168	0.000401	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—thyroid cancer	0.000168	0.000401	CcSEcCtD
Bosentan—Headache—Doxorubicin—thyroid cancer	0.000167	0.000398	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—SST—thyroid cancer	0.000165	0.00136	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TPR—thyroid cancer	0.000164	0.00135	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRG1—thyroid cancer	0.000162	0.00133	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PRKAR1A—thyroid cancer	0.000161	0.00133	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CALCA—thyroid cancer	0.000159	0.00131	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—thyroid cancer	0.000159	0.000378	CcSEcCtD
Bosentan—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000148	0.00122	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000146	0.0012	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TERT—thyroid cancer	0.000145	0.0012	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDK1—thyroid cancer	0.000144	0.00119	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HIF1A—thyroid cancer	0.000139	0.00114	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000133	0.00109	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000126	0.00104	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC5A5—thyroid cancer	0.000123	0.00101	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—NRAS—thyroid cancer	0.000122	0.00101	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000118	0.000974	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRG1—thyroid cancer	0.000116	0.000954	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000115	0.000948	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—BRAF—thyroid cancer	0.000115	0.000947	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—thyroid cancer	0.000105	0.000867	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TERT—thyroid cancer	0.000104	0.000856	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—RXRA—thyroid cancer	0.000103	0.00085	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.0001	0.000826	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HIF1A—thyroid cancer	9.93e-05	0.000819	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MINPP1—thyroid cancer	9.75e-05	0.000804	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HPGD—thyroid cancer	9.53e-05	0.000785	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—thyroid cancer	8.95e-05	0.000737	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—thyroid cancer	8.75e-05	0.000721	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—thyroid cancer	8.7e-05	0.000717	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—thyroid cancer	8.39e-05	0.000691	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NDUFA13—thyroid cancer	8.29e-05	0.000683	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—BRAF—thyroid cancer	8.23e-05	0.000678	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—thyroid cancer	8.1e-05	0.000667	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—thyroid cancer	7.9e-05	0.000651	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CHST14—thyroid cancer	7.8e-05	0.000643	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.73e-05	0.000637	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—thyroid cancer	7.53e-05	0.000621	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—thyroid cancer	7.22e-05	0.000595	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPARG—thyroid cancer	6.51e-05	0.000537	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—thyroid cancer	6.4e-05	0.000528	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPGD—thyroid cancer	6.28e-05	0.000518	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—thyroid cancer	6.23e-05	0.000513	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—thyroid cancer	6.22e-05	0.000512	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—thyroid cancer	6e-05	0.000495	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—thyroid cancer	5.8e-05	0.000478	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—thyroid cancer	5.65e-05	0.000466	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—thyroid cancer	5.53e-05	0.000455	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TPR—thyroid cancer	5.47e-05	0.000451	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	5.38e-05	0.000444	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—thyroid cancer	5.28e-05	0.000436	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—thyroid cancer	5.17e-05	0.000426	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—thyroid cancer	5.12e-05	0.000422	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.88e-05	0.000402	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—thyroid cancer	4.67e-05	0.000385	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—thyroid cancer	4.47e-05	0.000368	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—thyroid cancer	4.45e-05	0.000367	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.1e-05	0.000338	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—thyroid cancer	3.95e-05	0.000326	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.84e-05	0.000316	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—thyroid cancer	3.78e-05	0.000312	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TPR—thyroid cancer	3.61e-05	0.000297	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.55e-05	0.000293	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RXRA—thyroid cancer	3.44e-05	0.000284	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.35e-05	0.000276	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—thyroid cancer	3.34e-05	0.000275	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.7e-05	0.000223	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—thyroid cancer	2.57e-05	0.000212	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RXRA—thyroid cancer	2.27e-05	0.000187	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPARG—thyroid cancer	2.17e-05	0.000179	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.71e-05	0.000141	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—thyroid cancer	1.49e-05	0.000123	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPARG—thyroid cancer	1.43e-05	0.000118	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.13e-05	9.29e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—thyroid cancer	9.83e-06	8.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—thyroid cancer	8.59e-06	7.08e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—thyroid cancer	5.67e-06	4.67e-05	CbGpPWpGaD
